Top Page
Austco Healthcare Limited
(Sydney:AHC)
Austco Healthcare Limited (AHC) vs. iShares MSCI Australia ETF (EWA)
Austco Healthcare Limited Business Overview & Revenue Model
Austco Healthcare Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 81.41M | 81.41M | 58.15M | 41.98M | 35.88M | 31.25M |
| Gross Profit | 42.37M | 42.37M | 30.67M | 6.68M | 18.85M | 16.71M |
| EBITDA | 11.10M | 11.10M | 8.11M | 3.60M | 3.73M | 5.01M |
| Net Income | 5.93M | 5.93M | 7.08M | 2.26M | 2.33M | 3.42M |
Balance Sheet | ||||||
| Total Assets | 91.07M | 91.07M | 68.70M | 37.85M | 34.03M | 27.18M |
| Cash, Cash Equivalents and Short-Term Investments | 14.48M | 14.48M | 13.56M | 4.67M | 7.63M | 7.77M |
| Total Debt | 3.88M | 3.88M | 1.78M | 524.00K | 979.00K | 1.15M |
| Total Liabilities | 39.34M | 39.34M | 24.33M | 12.85M | 10.94M | 7.88M |
| Stockholders Equity | 51.73M | 51.73M | 44.38M | 25.00M | 23.09M | 19.30M |
Cash Flow | ||||||
| Free Cash Flow | 10.66M | 10.66M | 7.45M | -1.25M | 315.00K | 1.91M |
| Operating Cash Flow | 13.42M | 13.42M | 11.35M | 320.00K | 1.94M | 3.21M |
| Investing Cash Flow | -12.32M | -12.32M | -11.06M | -1.57M | -1.63M | -1.30M |
| Financing Cash Flow | -402.00K | -402.00K | 8.84M | -1.58M | -312.00K | -474.00K |
Austco Healthcare Limited Technical Analysis
Austco Healthcare Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$144.28M | 23.62 | 12.35% | ― | 39.98% | -30.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$2.01B | -54.02 | -44.49% | ― | 55.91% | 22.60% | |
50 Neutral | AU$107.25M | -7.99 | -31.98% | ― | 34.20% | -23.90% | |
47 Neutral | AU$102.96M | -23.04 | -4.28% | ― | 7.38% | 82.39% | |
40 Underperform | AU$80.06M | -11.23 | ― | ― | ― | ― | |
40 Underperform | AU$92.49M | -11.32 | -47.98% | ― | 700.00% | 26.88% |
Austco Healthcare Limited Corporate Events
Austco Healthcare Limited announced a change in the director’s interest, with Clayton Astles acquiring 632,649 unlisted performance rights. This grant, approved by shareholders at the recent Annual General Meeting, reflects the company’s commitment to aligning executive incentives with long-term performance goals, potentially impacting stakeholder confidence and company operations positively.
Austco Healthcare Limited announced the issuance of 632,649 performance rights as part of an employee incentive scheme. These unquoted securities are intended to motivate and retain employees, potentially impacting the company’s operational efficiency and competitive positioning in the healthcare technology market.
Austco Healthcare Limited reported a strong financial performance for FY2025, with a 40% increase in revenue to $81.4 million and a 62% rise in EBITDA to $13.0 million, achieving an EBITDA margin of 16%. The company is well-positioned for growth in the rapidly expanding global healthcare digitalization market, which is projected to grow significantly by 2031. With a debt-free balance sheet and substantial unfilled contract revenue, Austco Healthcare is poised for future earnings visibility and continued expansion.
Austco Healthcare Limited reported a record-breaking financial year in 2025, with a 40% increase in revenue to $81.4 million and a 62% growth in EBITDA to $13.0 million, driven by strong organic growth and successful integration of acquisitions. The company emphasized its strategic progress through acquisitions and innovation, investing significantly in research and development to maintain its leadership in healthcare communication systems. With a growing order book and a robust platform for expansion, Austco is well-positioned for continued growth and value delivery to shareholders and stakeholders.
Austco Healthcare Limited reported a strong start to the 2026 financial year with a 51% increase in revenue to $23.2 million and an improved EBITDA margin of 18.1%. This growth is attributed to both organic expansion and recent acquisitions, alongside operational efficiencies. The company continues to experience robust demand for its integrated nurse call, RTLS, and workflow solutions, positioning it well for sustained profitable growth. With a solid sales pipeline and continued efficiency gains, Austco targets 10–14% organic revenue growth for FY26.
Austco Healthcare Limited has announced the issuance of 2,159,408 Performance Rights under its Share Incentive Plan, with a performance period from July 2025 to June 2028. The vesting of these rights is contingent upon achieving specific EPS growth targets and indexed TSR benchmarks. Additionally, Austco plans to offer an additional 632,649 Performance Rights, pending shareholder approval at the upcoming AGM. This strategic move is likely aimed at aligning employee incentives with company performance, potentially enhancing Austco’s market position and shareholder value.
Austco Healthcare Limited has released a presentation for its FY 2025 roadshow, highlighting its commitment to growth through innovation. The presentation, authorized by the company’s Board, outlines the company’s strategic direction but does not constitute an offer for securities. The release emphasizes the company’s focus on innovation and its potential impact on operations and industry positioning, although it includes disclaimers regarding forward-looking statements and legal limitations.
Austco Healthcare Limited has announced that its Annual General Meeting (AGM) for 2025 will be held virtually on October 29, 2025, utilizing the Computershare meeting platform. This decision follows the Treasury Laws Amendment allowing virtual AGMs, enabling shareholders to participate online by viewing presentations, voting, and posing questions. The meeting will address ordinary business, including the consideration of financial statements and a non-binding resolution on the remuneration report. The company has outlined voting restrictions for key management personnel and their closely related parties, ensuring compliance with the Corporations Act.
Austco Healthcare Limited has issued 9,180,165 ordinary shares to the vendors of Amentco as part of the earnout agreement for Amentco’s acquisition, priced at $0.365 per share, totaling $3,350,760.79. Additionally, a cash payment of $5,026,141.19 was made to fulfill the company’s remaining earnout obligations, enhancing Austco’s strategic position in the healthcare communication sector.
Austco Healthcare Limited has announced the quotation of 9,180,165 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of September 23, 2025. This move is part of a previously announced transaction, potentially enhancing the company’s liquidity and market presence, which could positively impact its operations and stakeholders.
Austco Healthcare Limited announced a proposed issue of 9,180,165 ordinary fully paid securities, scheduled for September 23, 2025. This move is part of a placement or other type of issue, potentially impacting the company’s market positioning by increasing its capital base, which could be used for further development and expansion of its healthcare solutions.
Austco Healthcare Limited reported record revenues of $81.4 million for the fiscal year ending June 30, 2025, marking a 40% increase from the previous year. This growth was driven by both organic expansion and strategic acquisitions, with EBITDA rising by 62% to $13.0 million. The company has successfully integrated acquisitions like Teknocorp, Amentco, and G&S Technologies, which have expanded its capabilities and customer reach. Looking ahead, Austco plans to continue integrating new acquisitions, improve operating leverage, and sustain innovation through R&D investment, positioning itself for sustained growth in the healthcare communication and workflow solutions market.
Austco Healthcare Limited has announced the issuance of 71,645 fully paid ordinary securities under an employee incentive scheme, which will be quoted on the ASX. This move is likely to strengthen employee engagement and align their interests with the company’s growth objectives, potentially enhancing Austco’s market position and operational efficiency.
Austco Healthcare Limited announced the release of 10,256,410 fully paid ordinary shares from voluntary escrow, which were initially issued as part of the acquisition of Amentco in May 2024. This release, scheduled for 29 September 2025, signifies a strategic move in the company’s acquisition strategy, potentially impacting its market positioning and shareholder interests.
Austco Healthcare Limited has announced a change in the director’s interest, with Director James Brett Francis Burns acquiring an additional 59,264 ordinary shares through an on-market trade at $0.34 per share. This change reflects an increase in his direct holdings to 68,319 shares, while his indirect holdings remain at 1,400,282 shares. The acquisition of shares by a director may indicate confidence in the company’s future prospects, potentially impacting investor perceptions and market positioning.